Holen Sie sich die Stockscreener-App
23.33
0.69%
0.1817
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$23.15
Offen:
$23.67
24-Stunden-Volumen:
247.74K
Relative Volume:
0.06
Marktkapitalisierung:
$2.44B
Einnahmen:
$2.48B
Nettoeinkommen (Verlust:
$-57.96M
KGV:
-30.76
EPS:
-0.7585
Netto-Cashflow:
$-453.97M
1W Leistung:
+9.39%
1M Leistung:
+5.14%
6M Leistung:
+20.34%
1J Leistung:
-81.54%
1-Tages-Spanne:
$23.11
$23.67
1-Wochen-Bereich:
$20.86
$24.12
52-Wochen-Spanne:
$10.41
$128.75
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
23.33 | 2.43B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.17 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.41 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.40 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.73 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Wedbush | Outperform |
| 2025-11-05 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-09-22 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Is Sarepta Therapeutics Inc. stock resilient to inflationQuarterly Profit Summary & Daily Technical Stock Forecast Reports - ulpravda.ru
Why (SRPT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Sarepta Therapeutics seeks clinical trial clearance for SRP-1005 - BioWorld MedTech
Europe Gene Therapy Market to hit US$ 8,780.77 Million by 2033 | - openPR.com
Leerink Partners maintains Market Perform rating on Sarepta stock ahead of 2026 data - Investing.com UK
Assessing Sarepta Therapeutics (SRPT) Valuation After SRP-1005 Huntington’s Disease Trial Application - Yahoo Finance
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigat - pharmiweb.com
Sarepta submits clinical trial application for Huntington’s disease drug By Investing.com - Investing.com India
Sarepta submits clinical trial application for Huntington’s disease drug - Investing.com
Sarepta (SRPT) Moves Forward with New Clinical Trial Application for Huntington's Treatment - GuruFocus
Sarepta submits clinical trial application for Huntington's disease drug - StreetInsider
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease - Yahoo Finance
Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stock2026 world cup usa national team round of 32 star players high defensive line expert forecast preview - Улправда
Standing by Our Decision: How EXONDYS 51 Became Part of Our Treatment Plan - Muscular Dystrophy News
Buybacks Report: What risks investors should watch in Sarepta Therapeutics Inc stockBreakout Watch & Intraday High Probability Setup Alerts - moha.gov.vn
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - New Castle News
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: A Biotech Pioneer with a Mixed Valuation Outlook - DirectorsTalk Interviews
Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Cwm LLC - MarketBeat
United States Neuromuscular Disease Therapeutics Market - openPR.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2025 - BioSpace
Sarepta Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Voya Investment Management LLC Trims Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Reach - openPR.com
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny - MSN
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 - openPR.com
Japan Gene Therapy Market is expected to reach US$ 904.94 Million - openPR.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys - MSN
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Assenagon Asset Management S.A. Sells 838,457 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-Hours - MSN
Sarepta Therapeutics Earnings Notes - Trefis
Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Tuesday? (CORRECTED) - Benzinga
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 3.5%Here's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Sarepta to refinance $291M of existing notes due 2027 - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Reach Out - ACCESS Newswire
Aug Intraday: Will Sarepta Therapeutics Inc stock split attract more investorsOil Prices & Verified Momentum Stock Watchlist - moha.gov.vn
Have Insiders Sold Sarepta Therapeutics Shares Recently? - simplywall.st
How Sarepta Therapeutics Inc. stock compares to industry benchmarksPortfolio Gains Report & Real-Time Market Trend Scan - ulpravda.ru
Sarepta Therapeutics exchanges $291.4 million in convertible notes for new securities By Investing.com - Investing.com Nigeria
Sarepta Therapeutics Extends Debt Maturities with New Notes - TipRanks
Sarepta Therapeutics exchanges $291.4 million in convertible notes for new securities - Investing.com
Sarepta Therapeutics Signs Multiple Financing Agreements - TradingView — Track All Markets
What Does the Market Think About Sarepta Therapeutics Inc? - Benzinga
Is Sarepta Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Patterns & Reliable Price Action Trade Plans - DonanımHaber
Sarepta Therapeutics (NASDAQ:SRPT) COO Ian Michael Estepan Sells 13,187 Shares - MarketBeat
Insider Sale: Chief Operating Officer of $SRPT Sells 13,187 Shares - Quiver Quantitative
Sarepta Therapeutics COO Sells Shares - TradingView — Track All Markets
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):